对甲苯磺酸妥舒沙星水合物 | 1400591-39-0

• 物质功能分类: 生物化工 - 生化试剂 - 激动剂抑制剂
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: 对甲苯磺酸妥舒沙星水合物
• 英文名称: Tosufloxacin tosilate
• 英文别名: 7-(3-aminopyrrolidin-1-yl)-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid;4-methylbenzenesulfonic acid;hydrate
• CAS: 1400591-39-0
• 化学式: C26H25F3N4O7S
• 分子量: 594.6
• InChiKey: SSULTCPIIYRGFQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.46
• 重原子数：
  41
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  164
• 氢给体数：
  4
• 氢受体数：
  14

反应信息

• 作为产物：
  描述：

  ethyl 7-(3-acetylamino-1-pyrrolidinyl)-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylate 生成 对甲苯磺酸妥舒沙星水合物
  参考文献：
  名称：

  OXASI, OSAMU;TAKAKURA, ISAMU;KITANI, TEHTSUNORI;NIIMURA, TEHTSUDZO;NARITA+

  摘要：

  DOI：

文献信息

• EXTERNAL PREPARATION
  申请人：Teika Pharmaceutical Co., Ltd.

  公开号：EP3369422A1

  公开（公告）日：2018-09-05

  The present invention provides an external preparation that exerts excellent allergy treatment effects and comprises a combination of at least one ingredient (A) selected from the group consisting of ketotifen and pharmaceutically acceptable salts thereof; and at least one component (B) selected from the group consisting of quinolone antibacterial agents, saccharides, and inorganic salts.

  本发明提供了一种具有良好过敏治疗效果的外用制剂，由至少一种选自酮替芬及其药学上可接受的盐类的成分（A）和至少一种选自喹喏酮类抗菌剂、糖类和无机盐类的成分（B）组合而成。
• Freeze-dried pharmaceutical preparations for parenteral use
  申请人：KYORIN SEIYAKU KABUSHIKI KAISHA

  公开号：EP0322892B1

  公开（公告）日：1992-03-25
• OPHTHALMIC SOLUTION CONTAINER
  申请人：Fujimori Kogyo Co., Ltd.

  公开号：US20220055357A1

  公开（公告）日：2022-02-24

  An ophthalmic solution container has an accommodation part in which an ophthalmic solution is accommodated, and the accommodation part is composed of a laminate having a layer containing a cyclic olefin interpolymer (copolymer) and a layer containing a polyethylene resin provided outside the layer containing the cyclic olefin interpolymer (copolymer). The thickness of the layer containing the cyclic olefin interpolymer (copolymer) is 50 μm to 1,000 μm, and the thickness of the laminate is 300 μm to 2,000 μm. According to the container, it is possible to minimize sorption (adsorption and absorption) of the ophthalmic solution, it is possible to improve moisture barrier properties and minimize evaporation, and it is also possible to reduce the squeeze strength.
• US5188833A
  申请人：——

  公开号：US5188833A

  公开（公告）日：1993-02-23